EP 1 211 261 A2

EP 1 211 261 A25d) less than, or equal to, 15 percent by weight of the polymerized hemoglobin having a molecular weight over500,000 Daltons;e) less than, or equal to, 10 percent by weight of the polymerized hemoglobin having a molecular weight under65,000 Daltons; andf) less than, or equal to, 5 percent by weight of the hemoglobin having a molecular weight under 32,000 Daltons.1015[0347] Use of the stable polymerized hemoglobin solution for the manufacture of a medicament for increasing tissueoxygenation in the tissue of a vertebrate having reduced red blood cell flow.[0348] Use of the stable polymerized hemoglobin solution for the manufacture of a medicament for increasing tissueoxygenation or preventing oxygen depletion as a prophylaxis against reduced red blood cell flow.[0349] A method for increasing tissue oxygenation in the tissue of a vertebrate, wherein the tissue has reduced bloodcell flow, comprising introducing into the circulatory system of the vertebrate, at least one dose of hemoglobin.[0350] A method for increasing tissue oxygenation, or preventing oxygen depletion, in a vertebrate as a prophylaxisagainst reduced oxygenation as a consequence of a reduction in red blood cell flow in the vertebrate, comprisingintroducing into the circulatory system of the vertebrate at least one dose of hemoglobin.Claims202530351. Use of hemoglobin for the manufacture of a medicament for increasing organ function of a vertebrate, while theorgan has reduced oxygen delivery due to at least one partial obstruction of a blood vessel within the circulatorysystem of the vertebrate, and wherein the vertebrate has a normovolemic blood volume and at least a normalsystemic vascular resistance; by introducing into the circulatory system of the vertebrate at least one dose ofhemoglobin.2. A use of claim 1, wherein the organ is a muscle or a heart.3. A use of claim 2 wherein the organ is a heart which has a partial stenosis selected from a blood vessel stenosis,a valve stenosis, a stenosis of an opening in the heart and a stenosis of a chamber of the heart.4. A use of claim 1 wherein(a) the hemoglobin is in a hemoglobin solution of hemoglobin and a physiologically acceptable carrier, andoptionally wherein the hemoglobin solution is a polymerized hemoglobin solution, having for example a concentrationbetween about 120 grams of hemoglobin per liter and about 140 grams of hemoglobin per liter; or(b) the hemoglobin is in a physiologically acceptable suspension, optionally an emulsion.5. A use of claim 1 wherein:4045(a) the partial obstruction is a stenosis, optionally the result of a cause selected from a disease, a vessel wallabnormality, a compression, a chemical effect, vasoconstriction and vasospasms; or(b) the partial obstruction is an intravascular blockage, optionally selected from a thrombosis, an embolism,a foreign body and an infection.6. A use of claim 1 wherein the hemoglobin is administered:(a) therapeutically, or(b) prophylactically.50557. A use of claim 1 wherein the hemoglobin is injected into a vertebrate by an injection method selected from intravascularinjection, intracardial injection, intraperitoneal injection, subcutaneous injection, injection into a bone marrowof the vertebrate, and a combination thereof.8. Use of a polymerized hemoglobin solution for the manufacture of a medicament for increasing organ function ofa vertebrate, wherein the vertebrate has a normovolemic blood volume and at least a normal systemic vascularresistance, while the organ has reduced oxygen delivery due to at least one partial obstruction of a blood vesselwithin the circulatory system of the vertebrate; by introducing into the circulatory system of the vertebrate at leastone dose of said polymerized hemoglobin solution and wherein said hemoglobin solution has:38